Patents Assigned to Tularik Inc.
-
Patent number: 6794379Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.Type: GrantFiled: June 6, 2002Date of Patent: September 21, 2004Assignee: Tularik Inc.Inventors: Julio C. Medina, Michael G. Johnson, An-Rong Li
-
Publication number: 20040176426Abstract: The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&agr;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&ggr; and PPAR&agr;.Type: ApplicationFiled: March 4, 2004Publication date: September 9, 2004Applicant: Tularik, Inc.Inventors: Jonathan Houze, Sharon McKendry, Joshua P. Gergely, Yi Xia, Bei Shan, Frank Kayser
-
Publication number: 20040176409Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&ggr;. In particular, the compounds of the invention modulate the function of PPAR&ggr;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.Type: ApplicationFiled: November 20, 2003Publication date: September 9, 2004Applicants: Tularik Inc, Japan Tobacco, Inc.Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
-
Patent number: 6780858Abstract: Hydroxyamidines and related compounds are provided which are suitable as antibacterial agents.Type: GrantFiled: January 12, 2001Date of Patent: August 24, 2004Assignee: Tularik Inc.Inventors: Leping Li, Xiaoqi Chen, Pingchen Fan, Jeffrey Thomas Mihalic, Serena Cutler
-
Patent number: 6777446Abstract: The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&agr;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&ggr; and PPAR&agr;.Type: GrantFiled: August 31, 2001Date of Patent: August 17, 2004Assignee: Tularik, Inc.Inventors: Jonathan Houze, Sharon McKendry, Joshua P. Gergely, Yi Xia, Bei Shan, Frank Kayser
-
Publication number: 20040152132Abstract: The invention provides solid support synthetic methods for producing combinatorial libraries of modulators of LXRs. The combinatorial libraries thus produced are useful both as diagnostic indicators of LXR&agr; function and as pharmacologically active agents. The combinatorial libraries find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.Type: ApplicationFiled: December 30, 2003Publication date: August 5, 2004Applicants: Tularik Inc., Sumitomo Pharmaceuticals Co., Ltd.Inventors: Julio Medina, Naonori Imazaki
-
Patent number: 6770648Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.Type: GrantFiled: July 30, 2002Date of Patent: August 3, 2004Assignee: Tularik Inc.Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
-
Publication number: 20040097485Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.Type: ApplicationFiled: September 19, 2003Publication date: May 20, 2004Applicant: Tularik Inc.Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Andrew Smith, Marie-Louise Smith
-
Patent number: 6727267Abstract: Compounds, compositions and methods are provided that are useful in the treatment and prevention of certain viral infections and associated diseases. In particular, the compounds of the invention inhibit the activity of a viral RNA polymerase. The subject methods are particularly useful in the treatment of diseases causes by hepatitis C virus infection.Type: GrantFiled: April 5, 2001Date of Patent: April 27, 2004Assignee: Tularik Inc.Inventors: Juan C. Jaen, Jay P. Powers
-
Publication number: 20040039035Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.Type: ApplicationFiled: September 2, 2003Publication date: February 26, 2004Applicants: Tularik Inc., ChemoCentryx, Inc.Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
-
Publication number: 20040029232Abstract: The invention provides isolated nucleic acid and amino acid sequences of four novel G-protein coupled receptors that are amplified in breast cancer cells, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of G-protein coupled receptors.Type: ApplicationFiled: August 4, 2003Publication date: February 12, 2004Applicant: Tularik Inc.Inventors: Scott Powers, Jianxin Yang, Gene Cutler
-
Patent number: 6682898Abstract: This invention provides receptor peptides that have a high affinity for STAT4 and STAT6 polypeptides. Also provided are assays that are useful for identifying compounds that modulate the interaction between STAT4 and STAT6 polypeptides and their respective cellular promoters. The assays are amenable to high throughput screening.Type: GrantFiled: March 26, 2001Date of Patent: January 27, 2004Assignee: Tularik Inc.Inventors: Pengguang Wu, Judi McKinney
-
Publication number: 20040006068Abstract: Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.Type: ApplicationFiled: January 24, 2003Publication date: January 8, 2004Applicant: Tularik Inc.Inventors: Timothy D. Cushing, Heather L. Mellon, Juan C. Jaen, John A. Flygare, Shi-Chang Miao, Xiaoqi Chen, Jay P. Powers
-
Patent number: 6673543Abstract: The invention provides solid support synthetic methods for producing combinatorial libraries of modulators of LXRs. The combinatorial libraries thus produced are useful both as diagnostic indicators of LXR&agr; function and as pharmacologically active agents. The combinatorial libraries find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.Type: GrantFiled: April 4, 2001Date of Patent: January 6, 2004Assignees: Tularik, Inc., Sumitomo Pharmaceuticals Co., Ltd.Inventors: Julio Medina, Naonori Imazaki
-
Patent number: 6673923Abstract: The present invention provides pyrazole and pyrazolone derivatives. Preferred compounds of the invention are useful as RNA polymerase inhibitors. Further preferred compounds of the invention are useful as antimicrobial agents.Type: GrantFiled: May 2, 2001Date of Patent: January 6, 2004Assignee: Tularik Inc.Inventors: Leping Li, Xiaoqi Chen, Serena T. Cutler
-
Publication number: 20030229093Abstract: Arylsulfonamidobenzyl alcohols, amines and sulfonamides are provided which are useful in treating lipid disorders, metabolic diseases and cell-proliferative diseases.Type: ApplicationFiled: January 29, 2003Publication date: December 11, 2003Applicant: Tularik Inc.Inventors: Xian Yun Jiao, Frank Kayser, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
-
Publication number: 20030220339Abstract: Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.Type: ApplicationFiled: January 29, 2003Publication date: November 27, 2003Applicant: Tularik Inc.Inventors: Xian Yun Jiao, Frank Kayser, David J. Kopecky, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
-
Patent number: 6653332Abstract: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, &agr;-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound of Formula I is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound of Formula I.Type: GrantFiled: May 2, 2001Date of Patent: November 25, 2003Assignee: Tularik Inc.Inventors: Juan C. Jaen, Jin-Long Chen
-
Patent number: 6649593Abstract: Compounds, compositions and methods are provided for the inhibition of S1 protease and for the modulation of cholesterol homeostasis in a cell.Type: GrantFiled: October 6, 2000Date of Patent: November 18, 2003Assignees: Tularik Inc., Board of Regents, University of Texas SystemsInventors: Juan C. Jaen, Leping Li, Michael S. Brown, Joseph L. Goldstein, Dong Cheng
-
Patent number: 6638733Abstract: The invention provides isolated nucleic acid and amino acid sequences of four novel G-protein coupled receptors that are amplified in breast cancer cells, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of G-protein coupled receptors.Type: GrantFiled: March 14, 2000Date of Patent: October 28, 2003Assignee: Tularik Inc.Inventors: Scott Powers, Jianxin Yang, Gene Cutler